Certuity LLC Makes New Investment in Insulet Co. (NASDAQ:PODD)

Certuity LLC bought a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 939 shares of the medical instruments supplier's stock, valued at approximately $245,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. CWM LLC increased its position in shares of Insulet by 3.4% during the third quarter. CWM LLC now owns 3,984 shares of the medical instruments supplier's stock worth $927,000 after buying an additional 132 shares during the period. Exchange Traded Concepts LLC bought a new stake in Insulet during the third quarter valued at $121,000. Swedbank AB grew its holdings in Insulet by 3.2% during the 3rd quarter. Swedbank AB now owns 21,232 shares of the medical instruments supplier's stock worth $4,942,000 after acquiring an additional 655 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd raised its position in shares of Insulet by 3.0% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 6,453 shares of the medical instruments supplier's stock worth $1,502,000 after acquiring an additional 188 shares in the last quarter. Finally, Blue Trust Inc. lifted its stake in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 58 shares during the period.

Analysts Set New Price Targets

PODD has been the subject of several recent analyst reports. JPMorgan Chase & Co. raised their target price on Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research note on Thursday, December 12th. Barclays lifted their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Wells Fargo & Company increased their target price on shares of Insulet from $290.00 to $305.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 11th. TD Cowen raised their price target on shares of Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, January 3rd. Finally, Canaccord Genuity Group upped their price objective on shares of Insulet from $269.00 to $304.00 and gave the company a "buy" rating in a report on Monday, December 9th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of "Moderate Buy" and a consensus price target of $277.13.

Insider Activity at Insulet

In related news, CAO Lauren Budden sold 915 shares of the firm's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company's stock, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Eric Benjamin sold 12,394 shares of the company's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares of the company's stock, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by insiders.

Insulet Stock Down 0.6 %

PODD traded down $1.56 during midday trading on Monday, reaching $280.56. 474,733 shares of the company were exchanged, compared to its average volume of 522,338. Insulet Co. has a one year low of $160.19 and a one year high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company's fifty day moving average price is $272.05 and its 200 day moving average price is $245.32. The company has a market cap of $19.68 billion, a price-to-earnings ratio of 48.04, a price-to-earnings-growth ratio of 3.61 and a beta of 1.23.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.